Modulation of S1P in the Treatment of Autoimmune Diseases
We recommend
Long-term treatment of ozanimod in patients with moderate to severe ulcerative colitis
The immunosuppressive ozanimod was approved for the treatment of ulcerative colitis (UC) based on the results of the phase III clinical trial True North. An open-label study followed this and previous clinical evaluations, focusing particularly on the efficacy of long-term use of ozanimod. What insights did the subsequent monitoring bring?
Ozanimod Expands Treatment Options for Ulcerative Colitis in Adult Patients
As a review article published last year in the journal Drugs suggests, ozanimod is an effective and…
Ozanimod in Induction and Maintenance Therapy for Ulcerative Colitis − True North Study Results
Ozanimod is a selective modulator of the sphingosine-1-phosphate receptor (S1PR) approved for the…
Articles on this topic
Invitation to ZEPOSIA STAND ALONE MEETING
On behalf of Bristol Myers Squibb, we warmly invite you to the Zeposia Stand Alone Meeting, which...
Subscribe
Most read on this topic
Journal on this topic
Related topic
Interesting links
Most read on this topic
- Ozanimod Expands Treatment Options for Ulcerative Colitis in Adult Patients
- Invitation to ZEPOSIA STAND ALONE MEETING
- Long-term treatment of ozanimod in patients with moderate to severe ulcerative colitis
- Ozanimod in Induction and Maintenance Therapy for Ulcerative Colitis − True North Study Results
Journal on this topic
Related topic
Interesting links